← Human Trials & Peer-Reviewed Studies
A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus
Plain-language guide to PMID 14648410 (2003): crossover randomized controlled trial study of Methylene blue (non-peptide stack partner).
Key Facts
- PMID
- 14648410
- Journal
- Endoscopy
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Ragunath K et al. (5 authors)
- DOI
- 10.1055/s-2003-44599
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).
The value of methylene blue-directed biopsies (MBDB) in detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus remains unclear.
The aim of this study was to compare the accuracy of MBDB with random biopsy in detecting intestinal metaplasia and dysplasia in patients with Barrett's esophagus.
A prospective, randomized, cross-over trial was undertaken to compare MBDB with random biopsy in patients with Barrett's esophagus segments 3 cm or more in length without macroscopic evidence of dysplasia or cancer.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized and crossover study.
Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.
In the crossover set-up each of the participants took both Methylene blue (non-peptide stack partner) and the comparison in turn, acting as their own control.
Dysplasia was graded as: indefinite for dysplasia, low-grade dysplasia, high-grade dysplasia, or carcinoma, and was reported in a blinded fashion.
What Was Measured
PubMed files the paper under topics including Barrett Esophagus, Biopsy, Endoscopy, Gastrointestinal, Intestines, Metaplasia and Methylene Blue.
What This Means in Plain Language
The paper is a randomized and crossover study of Methylene blue (non-peptide stack partner).
Its findings take up roughly 13 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2003 (Endoscopy), a journal based in Germany.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.